LataMed AI Corp. (OTC: LMED) provided shareholders with an update on the implementation of its previously announced 5-for-1 forward stock split and related mandatory share exchange process. As of July 7, 2026, the Company has submitted all required information to FINRA, and management anticipates the corporate action may become effective within approximately the next week, pending FINRA's review and final processing.
The forward stock split will be accompanied by a new CUSIP number, 21116R404, to facilitate the mandatory exchange. Shareholders holding shares through brokerage accounts are generally not required to take any action, as the exchange will be processed automatically. Registered book-entry shareholders also do not need to submit documentation, as the transfer agent will update accounts automatically. However, holders of physical stock certificates are advised that existing certificates will represent the pre-exchange security; upon submission for transfer, sale, or exchange, they will receive post-split shares under the new CUSIP.
Dr. Kevin Rodan Levy, CEO, stated: “We want to ensure that our shareholders clearly understand how the forward stock split and mandatory exchange process will be implemented. While the vast majority of shareholders are expected to have their shares updated automatically, we believe it is important to provide clear guidance for physical certificate holders.” He added that the Company intends to focus on advancing its telemedicine platform and pursuing licensing opportunities for its CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms, which are key to building an integrated digital healthcare ecosystem in Latin America.
Management believes the forward stock split supports corporate development and strategic initiatives. The Company encourages shareholders with questions to contact their brokerage firm or the Company's transfer agent once detailed instructions are available. For more information, visit https://latamed.ai or review SEC filings at www.sec.gov.
This press release contains forward-looking statements regarding the Company's business strategy, corporate actions, and platform deployment. Actual results may differ materially due to risks including the ability to implement the stock split, obtain regulatory approvals, and execute the business plan. The Company undertakes no obligation to update forward-looking statements.
